Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Prostanoid DP receptor variants and asthma

Aaron Deykin

    The New England Journal of Medicine
    |March 1, 2005
    PubMed
    Summary

    No abstract available in PubMed .

    Related Experiment Videos

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Safety and efficacy of opicinumab in participants with relapsing multiple sclerosis (AFFINITY Part 1): A randomized, controlled, phase 2 trial.

    Multiple sclerosis (Houndmills, Basingstoke, England)·2025
    Same author

    Verekitug, a Novel Antibody Antagonist to the TSLP Receptor in Adults with Asthma: A 32-Week Randomized Phase 1b Multiple Ascending-Dose Trial.

    Clinical pharmacology and therapeutics·2025
    Same author

    Overall Disability Response Score: An integrated endpoint to assess disability improvement and worsening over time in patients with multiple sclerosis.

    Multiple sclerosis (Houndmills, Basingstoke, England)·2022
    Same author

    Temporal profile of serum neurofilament light in multiple sclerosis: Implications for patient monitoring.

    Multiple sclerosis (Houndmills, Basingstoke, England)·2020
    Same author

    Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial.

    The Lancet. Neurology·2019
    Same author

    Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension.

    The Lancet. Neurology·2018
    Same journal

    Sparganosis.

    The New England journal of medicine·2026
    Same journal

    Caring for an Aging America - The Looming Crisis of the Long-Term-Care Workforce.

    The New England journal of medicine·2026
    Same journal

    For Those Left Behind.

    The New England journal of medicine·2026
    Same journal

    Colliding Forces - The Aging of the Baby Boom Generation and Contracting Nursing-Home Supply.

    The New England journal of medicine·2026
    Same journal

    Mandated State-Level Surveillance of Assisted Reproductive Technology - An Emerging Threat in the United States.

    The New England journal of medicine·2026
    Same journal

    Ebola at 50 - Lessons for Outbreak Response and Preparedness.

    The New England journal of medicine·2026
    See all related articles